Trends in the Use of Sedative-Hypnotics, Opioids, and Neuromuscular Blockers in Hospitalized Patients During the COVID-19 Pandemic: Observational Retrospective Study
Tóm tắt
The coronavirus disease 2019 (COVID-19) pandemic has increased the use of drugs administered for mechanical ventilation, leading to shortages in some countries. The aim was to identify trends in the consumption of sedatives, hypnotics, neuromuscular blockers, and opioids used for anesthetic induction and deep sedation in hospitals in Colombia. This was a descriptive, longitudinal, and retrospective study with monthly follow-up of sedative, hypnotic, opioid, and neuromuscular blocker dispensing in 20 clinics and hospitals from January to November 2020. The frequencies of use of each drug and variations in the institutions and intensive care units (ICUs) were identified. A total of 1,252,576 units of the analyzed drugs were delivered to 79,094 treated patients, 55.0% of whom were women (n = 43,521). The drugs with the greatest increase in consumption were rocuronium (1058% variation in March–November) and propofol (511%). The consumption of midazolam and vecuronium initially increased, but by the end of the study period, it decreased. Among drugs dispensed only in ICUs, 920,170 units were delivered (73.5% of the drugs dispensed during the study), and the most often dispensed drugs were fentanyl (n = 251,519; 27.3% of the drugs used in the ICU) and midazolam (5 mg/5 mL) solution (n = 188,568; 20.5%). Specifically in the ICU, the drugs with the greatest increase in use were rocuronium (19,709%), propofol (2622%), and ketamine (2591%). Rapid changes in the use of drugs were evident, which demonstrates the need for closer cooperation among treating physicians, service providers, pharmaceutical managers, and state institutions to maintain a sufficient and timely supply of critical drugs in this type of contingency.
Tài liệu tham khảo
Parthasarathy P, Vivekanandan S. An extensive study on the COVID-19 pandemic, an emerging global crisis: risks, transmission, impacts and mitigation. J Infect Public Health. 2020;14(2):249–59. https://doi.org/10.1016/j.jiph.2020.12.020.
Bellani G, Laffey JG, Pham T, LUNG SAFE Investigators; ESICM Trials Group, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–800. https://doi.org/10.1001/jama.2016.0291.
Total de camas UCI en el país para la atención de covid-19 incrementó 91%—Boletín de Prensa No 684 de 2020 [press release]. Bogotá D.C: Ministerio de Salud de Colombia, 07/09/2020 2020. Cited: Jan 2021. Available from: https://www.minsalud.gov.co/Paginas/Total-de-camas-UCI-en-el-pais-para-la-atencion-de-covid-19-incremento-91.aspx.
SaluData. Observatorio de Salud de Bogotá. Secretaria de Salud de Bogotá Bogotá, Colombia. 2020. Available from: https://saludata.saludcapital.gov.co/osb/index.php/datos-de-salud/enfermedades-trasmisibles/ocupacion-ucis/.
Payen JF, Chanques G, Futier E, Velly L, Jaber S, Constantin JM. Sedation for critically ill patients with COVID-19: which specificities? One size does not fit all. Anaesth Crit Care Pain Med. 2020;39(3):341–3. https://doi.org/10.1016/j.accpm.2020.04.010.
Chanques G, Drouot X, Payen JF. 2008–2018: ten years of gradual changes in the sedation guidelines for critically ill patients. Anaesth Crit Care Pain Med. 2018;37(6):509–11. https://doi.org/10.1016/j.accpm.2018.10.014.
Montmeat D, Gard C, Raux M, Constantin JM, Tilleul P. Shortage of sedatives and neuromuscular blockers during COVID-19 pandemic: the result of an overstocking procedure in French hospitals? Anaesth Crit Care Pain Med. 2020;39(5):585–6. https://doi.org/10.1016/j.accpm.2020.06.013.
Ministerio de Salud de Colombia. Casos positivos de COVID-19 en Colombia. Cited: August of 2022. Available from: https://www.datos.gov.co/Salud-y-Protecci-n-Social/Casos-positivos-de-COVID-19-en-Colombia/gt2j-8ykr/data.
Accini José LBN, Cárdenas Y, Ciro Juan D, Cotes R, Díaz Juan C, Dueñas C, Garay M, Gil B, González M, López D, Meléndez H, Ortiz G, Pizarro C. Alternativas Farmacológicas para el abordaje de la sedación, analgesia, relajación y delirium en el paciente Covid-19. Bogotá, Colombia: Asociación Colombiana de Medicina Crítica y Cuidado Intensivo; 2020. Cited: August of 2022. Available from: https://www.amci.org.co/alternativas-farmacologicas-de-sedacion-analgesia-relajacion-y-delirium-en-covid-19.
Flinspach AN, Booke H, Zacharowski K, Balaban U, Herrmann E, Adam EH. Associated factors of high sedative requirements within patients with moderate to severe COVID-19 ARDS. J Clin Med. 2022. https://doi.org/10.3390/jcm11030588.
Ego A, Peluso L, Gorham J, Diosdado A, Restuccia G, Creteur J, et al. Use of sedatives and neuromuscular-blocking agents in mechanically ventilated patients with COVID-19 ARDS. Microorganisms. 2021. https://doi.org/10.3390/microorganisms9112393.
Chapuis C, Collomp R, Albaladejo L, Terrisse H, Honore S, Bosson JL, et al. Redistribution of critical drugs in shortage during the first wave of COVID-19 in France: from operating theaters to intensive care units. J Pharm Policy Pract. 2022;15(1):28. https://doi.org/10.1186/s40545-022-00425-z.
Oehler RL, Gompf SG. Shortcomings in the US pharmaceutical supply chain: potential risks associated with international manufacturing and trade-related tariffs. JAMA. 2020;324(2):143–4. https://doi.org/10.1001/jama.2020.1634.
Ministerio de Salud y Protección Social. Comunicado: Recomendaciones para el manejo de medicamentos en riesgo alto de desabastecimiento y oxígeno medicinal. Bogotá. 2021. Cited: August of 2022. https://www.minsalud.gov.co/Paginas/Minsalud-definio-estrategias-ante-desabastecimiento-de-medicamentos.aspx.
Asociación Colombiana de Medicina Crítica y Cuidado Intensivo, Sociedad Colombiana de Anestesiología. Alternativas farmacológicas para el abordaje de la Sedación, Analgesia, Relajación y Delirium en paciente COVID-19. Anexo 5: Uso de agentes anestésicos inhalatorios como alternativa válida en la sedación de los pacientes hospitalizados en las unidades de cuidado intensivo de Colombia. 2020. Cited: August of 2022. Available from: https://amci.org.co/images/PDF_AMCI/Anexo_5_Sedacion_Inhalatoria_S.C.A.R.E._-_AMCI.PDF.
Landoni G, Belloni O, Russo G, Bonaccorso A, Cara G, Jabaudon M. Inhaled sedation for invasively ventilated COVID-19 patients: a systematic review. J Clin Med. 2022. https://doi.org/10.3390/jcm11092500.
Ferriere N, Bodenes L, Bailly P, L’Her E. Shortage of anesthetics: think of inhaled sedation! J Crit Care. 2021;63:104–5. https://doi.org/10.1016/j.jcrc.2020.09.009.
Au Yong PSA, Kwa CWX, Chan XHD. Anaesthetic considerations for rationalizing drug use in the operating theatre: strategies in a Singapore Hospital during COVID-19. SN Compr Clin Med. 2020;2(7):871–3. https://doi.org/10.1007/s42399-020-00345-6.
Ammar MA, Sacha GL, Welch SC, Bass SN, Kane-Gill SL, Duggal A, et al. Sedation, analgesia, and paralysis in COVID-19 patients in the setting of drug shortages. J Intensive Care Med. 2021;36(2):157–74. https://doi.org/10.1177/0885066620951426.
Food and Drug Administration. Drug shortages for calendar year 2021. Report to Congress. 2021. Cited: August of 2022. Available from: https://www.fda.gov/media/159302/download.
Padhan S, Pugazhenthan T, Chandrakar R, Galhotra A, Borkar NB. Assessment of the impact of COVID-19 on drug store management in a Tertiary Care Teaching Hospital of Central India. Cureus. 2021;13(11):e19723. https://doi.org/10.7759/cureus.19723.
Ammassari A, Di Filippo A, Trotta MP, Traversa G, Pierantozzi A, Trotta F, et al. Comparison of demand for drugs used for COVID-19 treatment and other drugs during the early phase of the COVID-19 pandemic in Italy. JAMA Netw Open. 2021;4(2):e2037060. https://doi.org/10.1001/jamanetworkopen.2020.37060.
Orser BA, Wang DS, Lu WY. Sedating ventilated COVID-19 patients with inhalational anesthetic drugs. EBioMedicine. 2020;55:102770. https://doi.org/10.1016/j.ebiom.2020.102770.
Alexander GC, Qato DM. Ensuring access to medications in the US during the COVID-19 pandemic. JAMA. 2020;324(1):31–2. https://doi.org/10.1001/jama.2020.6016.
Gerard A, Romani S, Fresse A, Viard D, Parassol N, Granvuillemin A, et al. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie. 2020;75(4):371–9.